Literature DB >> 1995891

Configuration and preferential solid-state conformations of perindoprilat (S-9780). Comparison with the crystal structures of other ACE inhibitors and conclusions related to structure-activity relationships.

C Pascard1, J Guilhem, M Vincent, G Rémond, B Portevin, M Laubie.   

Abstract

The conformation of perindoprilat, an antihypertensive drug, is studied in the solid state by X-ray analysis. The resolution of its structure reveals important analogies between its observed conformation and that of several ACE inhibitors of the same family. This comparison points out a constant relative orientation of the functional groups, regardless of the molecular environment. This angular constancy appears to us as not being accidental and is a good argument for the spatial design of the ACE binding site. Although ACE is a carboxydipeptidase, the binding site may not contain two but one unique hydrophobic pocket receiving the C-terminal end of the inhibitors.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1995891     DOI: 10.1021/jm00106a030

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  4 in total

1.  Controlled release and angiotensin-converting enzyme inhibition properties of an antihypertensive drug based on a perindopril erbumine-layered double hydroxide nanocomposite.

Authors:  Samer Hasan Hussein Al Ali; Mothanna Al-Qubaisi; Mohd Zobir Hussein; Maznah Ismail; Zulkarnain Zainal; Muhammad Nazrul Hakim
Journal:  Int J Nanomedicine       Date:  2012-04-24

2.  The Development and Validation of a Stability-Indicating UHPLC-DAD Method for Determination of Perindopril l-Arginine in Bulk Substance and Pharmaceutical Dosage Form.

Authors:  Magdalena Paczkowska; Przemysław Zalewski; Piotr Garbacki; Alicja Talaczyńska; Anna Krause; Judyta Cielecka-Piontek
Journal:  Chromatographia       Date:  2014-08-13       Impact factor: 2.044

3.  Comparative study of Mg/Al- and Zn/Al-layered double hydroxide-perindopril erbumine nanocomposites for inhibition of angiotensin-converting enzyme.

Authors:  Samer Hasan Hussein Al Ali; Mothanna Al-Qubaisi; Mohd Zobir Hussein; Maznah Ismail; Zulkarnain Zainal; Muhammad Nazrul Hakim
Journal:  Int J Nanomedicine       Date:  2012-08-03

4.  Sustained release of prindopril erbumine from its chitosan-coated magnetic nanoparticles for biomedical applications.

Authors:  Dena Dorniani; Mohd Zobir Bin Hussein; Aminu Umar Kura; Sharida Fakurazi; Abdul Halim Shaari; Zalinah Ahmad
Journal:  Int J Mol Sci       Date:  2013-12-03       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.